Jeffrey T Ha, Anish Scaria, Jason Andrade, Sunil V Badve, Peter Birks, Sarah E Bota, Anna Campain, Ognjenka Djurdjev, Amit X Garg, Ziv Harel, Brenda Hemmelgarn, Carinna Hockham, Matthew T James, Meg J Jardine, Dickson Lam, Adeera Levin, Eric McArthur, Pietro Ravani, Selena Shao, Manish M Sood, Zhi Tan, Navdeep Tangri, Reid Whitlock, Martin Gallagher, Min Jun
RATIONALE & OBJECTIVE: The benefit-risk profile of rivaroxaban versus warfarin for atrial fibrillation (AF) in patients with chronic kidney disease is uncertain. We compared rivaroxaban with warfarin across the range of kidney function in adults with AF. STUDY DESIGN: Multicenter retrospective cohort. SETTING & PARTICIPANTS: Adults with AF and a measure of estimated glomerular filtration rate (eGFR); using administrative data from 5 jurisdictions across Australia and Canada (2011-2018)...
July 2023: Kidney medicine